Loading...

Blower, Sally M

Title(s)Professor-in-Residence, Psychiatry And Biobehavioral Sciences
Phone43933
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Optimal Strategies for HIV Treatment and Prevention in Sub-Saharan Africa
    NIH/NIAID R01AI116493Aug 1, 2015 - Jan 31, 2020
    Role: Principal Investigator
    Determining whether TasP could eliminate HIV in resource-rich countries
    NIH/NIAID R21AI114478Jun 15, 2014 - May 31, 2016
    Role: Principal Investigator
    Designing optimal interventions to control HIV in Africa using data-based models
    NIH/NIAID R21AI086701Jul 1, 2010 - Jun 30, 2012
    Role: Principal Investigator
    HIV - Emergence of Drug Resistance
    NIH/NIAID R56AI041935May 1, 1998 - Jul 31, 2015
    Role: Principal Investigator
    HIV - Emergence of Drug Resistance
    NIH/NIAID R01AI041935May 1, 1998 - Sep 19, 2011
    Role: Principal Investigator
    DIFFUSION OF HIV EPIDEMICS
    NIH/NIDA R29DA008153Mar 1, 1993 - Feb 28, 1998
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Okano JT, Sharp K, Valdano E, Palk L, Blower S. HIV transmission and source-sink dynamics in sub-Saharan Africa. Lancet HIV. 2020 Mar; 7(3):e209-e214. PMID: 32066532.
      View in: PubMed
    2. Valdano E, Blower S. Universal Testing and Treatment for HIV Infection in Botswana. N Engl J Med. 2019 11 28; 381(22):2180. PMID: 31774970.
      View in: PubMed
    3. Blower S, Okano JT. Precision public health and HIV in Africa. Lancet Infect Dis. 2019 Oct; 19(10):1050-1052. PMID: 31559952.
      View in: PubMed
    4. Okano JT, Blower S. New conceptual framework for tuberculosis transmission. Lancet Infect Dis. 2019 Jun; 19(6):578. PMID: 31122773.
      View in: PubMed
    5. Palk L, Gerstoft J, Obel N, Blower S. A modeling study of the Danish HIV epidemic in men who have sex with men: travel, pre-exposure prophylaxis and elimination. Sci Rep. 2018 10 30; 8(1):16003. PMID: 30375426.
      View in: PubMed
    6. Palk L, Blower S. Geographic variation in sexual behavior can explain geospatial heterogeneity in the severity of the HIV epidemic in Malawi. BMC Med. 2018 02 09; 16(1):22. PMID: 29422096.
      View in: PubMed
    7. Okano JT, Coburn BJ, Blower S. Response to comment on "Using geospatial mapping to design HIV elimination strategies for sub-Saharan Africa". Sci Transl Med. 2017 Aug 02; 9(401). PMID: 28768805.
      View in: PubMed
    8. Blower S, Palk L. Methodological concerns regarding a PrEP model. Lancet Infect Dis. 2017 05; 17(5):482. PMID: 28447954.
      View in: PubMed
    9. Coburn BJ, Okano JT, Blower S. Using geospatial mapping to design HIV elimination strategies for sub-Saharan Africa. Sci Transl Med. 2017 03 29; 9(383). PMID: 28356504.
      View in: PubMed
    10. Okano JT, Blower S. Sex-specific maps of HIV epidemics in sub-Saharan Africa. Lancet Infect Dis. 2016 12; 16(12):1320-1322. PMID: 27998582.
      View in: PubMed
    11. Okano JT, Gerstoft J, Obel N, Blower S. HIV elimination and population viral load. Lancet HIV. 2016 11; 3(11):e507-e509. PMID: 27788865.
      View in: PubMed
    12. Okano JT, Robbins D, Palk L, Gerstoft J, Obel N, Blower S. Testing the hypothesis that treatment can eliminate HIV: a nationwide, population-based study of the Danish HIV epidemic in men who have sex with men. Lancet Infect Dis. 2016 07; 16(7):789-796. PMID: 27174504.
      View in: PubMed
    13. Palk L, Blower S. Mapping divided households and residency changes: the effect of couple separation on sexual behavior and risk of HIV infection. Sci Rep. 2015 Dec 02; 5:17598. PMID: 26626310.
      View in: PubMed
    14. Supervie V, Barrett M, Kahn JS, Musuka G, Moeti TL, Busang L, Blower S. Corrigendum: Modeling dynamic interactions between pre-exposure prophylaxis interventions &treatment programs: predicting HIV transmission &resistance. Sci Rep. 2015 Sep 18; 5:13037. PMID: 26384032.
      View in: PubMed
    15. Palk L, Blower S. Brief report: Mobility and circular migration in Lesotho: implications for transmission, treatment, and control of a severe HIV epidemic. J Acquir Immune Defic Syndr. 2015 Apr 15; 68(5):604-8. PMID: 25763787.
      View in: PubMed
    16. Blower S, Palk L. Combination HIV prevention and the battle of the sexes. Lancet Infect Dis. 2015 Mar; 15(3):261-3. PMID: 25749218.
      View in: PubMed
    17. Gerberry DJ, Wagner BG, Garcia-Lerma JG, Heneine W, Blower S. Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in Sub-Saharan Africa. Nat Commun. 2014 Dec 02; 5:5454. PMID: 25462707.
      View in: PubMed
    18. Blower S, Coburn BJ. Maximising the effect of combination HIV prevention in Kenya. Lancet. 2014 Oct 18; 384(9952):1426. PMID: 25390322.
      View in: PubMed
    19. Okano JT, Blower S. Beware of using invalid transmission models to guide HIV health policy. Lancet Glob Health. 2014 May; 2(5):e260. PMID: 25103162.
      View in: PubMed
    20. Coburn BJ, Blower S. Predicting the potential for within-flight transmission and global dissemination of MERS. Lancet Infect Dis. 2014 Feb; 14(2):99. PMID: 24457166.
      View in: PubMed
    21. Coburn BJ, Blower S. Mapping HIV epidemics in sub-Saharan Africa with use of GPS data. Lancet Glob Health. 2013 Nov; 1(5):e251-3. PMID: 25104487.
      View in: PubMed
    22. Coburn BJ, Okano JT, Blower S. Current drivers and geographic patterns of HIV in Lesotho: implications for treatment and prevention in Sub-Saharan Africa. BMC Med. 2013 Oct 16; 11:224. PMID: 24131484.
      View in: PubMed
    23. Okano JT, Blower S. HIV treatment, preexposure prophylaxis, and drug resistance: reconciling conflicting predictions from mathematical models. J Infect Dis. 2014 Jan 01; 209(1):163-4. PMID: 24133183.
      View in: PubMed
    24. Wagner BG, Coburn BJ, Blower S. Increasing survival time decreases the cost-effectiveness of using "test & treat'' to eliminate HIV epidemics. Math Biosci Eng. 2013 Oct-Dec; 10(5-6):1673-86. PMID: 24245641.
      View in: PubMed
    25. Coburn BJ, Blower S. A feasibility analysis of implementing interventions for discordant couples in 14 African countries: implications for epidemic control. AIDS. 2012 Sep 24; 26(15):1969-71. PMID: 22824631.
      View in: PubMed
    26. Wagner BG, Blower S. Universal access to HIV treatment versus universal 'test and treat': transmission, drug resistance & treatment costs. PLoS One. 2012; 7(9):e41212. PMID: 22957012.
      View in: PubMed
    27. Wagner BG, Garcia-Lerma JG, Blower S. Factors limiting the transmission of HIV mutations conferring drug resistance: fitness costs and genetic bottlenecks. Sci Rep. 2012; 2:320. PMID: 22432052.
      View in: PubMed
    28. Supervie V, Barrett M, Kahn JS, Musuka G, Moeti TL, Busang L, Busang L, Blower S. Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistance. Sci Rep. 2011; 1:185. PMID: 22355700.
      View in: PubMed
    29. El-Sadr WM, Coburn BJ, Blower S. Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS. 2011 Nov 28; 25(18):2295-9. PMID: 21993304.
      View in: PubMed
    30. Yasmin S, Gerberry DJ, Blower S. Human papillomavirus vaccination programs and human immunodeficiency virus epidemics. Clin Infect Dis. 2011 Oct; 53(8):845-6. PMID: 21921228.
      View in: PubMed
    31. Coburn BJ, Gerberry DJ, Blower S. Quantification of the role of discordant couples in driving incidence of HIV in sub-Saharan Africa. Lancet Infect Dis. 2011 Apr; 11(4):263-4. PMID: 21453868.
      View in: PubMed
    32. Supervie V, Halima Y, Blower S. Assessing the impact of mass rape on the incidence of HIV in conflict-affected countries. AIDS. 2010 Nov 27; 24(18):2841-7. PMID: 20859191.
      View in: PubMed
    33. Wagner B, Blower S. Costs of eliminating HIV in South Africa have been underestimated. Lancet. 2010 Sep 18; 376(9745):953-4. PMID: 20851250.
      View in: PubMed
    34. Supervie V, García-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A. 2010 Jul 06; 107(27):12381-6. PMID: 20616092.
      View in: PubMed
    35. Gerberry DJ, Blower S. Predicting the level of vaccine-induced cross-immunity necessary to eliminate HIV epidemics composed of multiple subtypes. AIDS. 2010 Jun 19; 24(10):1604-406. PMID: 20539095.
      View in: PubMed
    36. Coburn BJ, Blower S. A major HIV risk factor for young men who have sex with men is sex with older partners. J Acquir Immune Defic Syndr. 2010 Jun; 54(2):113-4. PMID: 20335817.
      View in: PubMed
    37. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science. 2010 Feb 05; 327(5966):697-701. PMID: 20075214.
      View in: PubMed
    38. Okano JT, Blower S. Are correctional facilities amplifying the epidemic of community-acquired methicillin-resistant Staphylococcus aureus? Nat Rev Microbiol. 2010 Jan; 8(1):83. PMID: 20010953.
      View in: PubMed
    39. Wagner BG, Coburn BJ, Blower S. Calculating the potential for within-flight transmission of influenza A (H1N1). BMC Med. 2009 Dec 24; 7:81. PMID: 20034378.
      View in: PubMed
    40. Breban R, Napravnik S, Kahn J, Blower S. Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling. BMC Public Health. 2009 Nov 18; 9 Suppl 1:S11. PMID: 19922681.
      View in: PubMed
    41. Coburn BJ, Wagner BG, Blower S. Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1). BMC Med. 2009 Jun 22; 7:30. PMID: 19545404.
      View in: PubMed
    42. Breban R, Supervie V, Okano JT, Vardavas R, Blower S. Is there any evidence that syphilis epidemics cycle? Lancet Infect Dis. 2008 Sep; 8(9):577-81. PMID: 18718441.
      View in: PubMed
    43. Wilson DP, Coplan PM, Wainberg MA, Blower SM. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci U S A. 2008 Jul 15; 105(28):9835-40. PMID: 18606986.
      View in: PubMed
    44. Fenton KA, Breban R, Vardavas R, Okano JT, Martin T, Aral S, Blower S. Infectious syphilis in high-income settings in the 21st century. Lancet Infect Dis. 2008 Apr; 8(4):244-53. PMID: 18353265.
      View in: PubMed
    45. Schwartz EJ, Bodine EN, Blower S. Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines. Hum Vaccin. 2007 Nov-Dec; 3(6):231-8. PMID: 17881889.
      View in: PubMed
    46. Breban R, Vardavas R, Blower S. Mean-field analysis of an inductive reasoning game: application to influenza vaccination. Phys Rev E Stat Nonlin Soft Matter Phys. 2007 Sep; 76(3 Pt 1):031127. PMID: 17930219.
      View in: PubMed
    47. Kajita E, Okano JT, Bodine EN, Layne SP, Blower S. Modelling an outbreak of an emerging pathogen. Nat Rev Microbiol. 2007 09; 5(9):700-9. PMID: 17703226.
      View in: PubMed
    48. Blower S, Supervie V. Predicting the future of XDR tuberculosis. Lancet Infect Dis. 2007 Jul; 7(7):443. PMID: 17597567.
      View in: PubMed
    49. Wilson DP, Blower S. How far will we need to go to reach HIV-infected people in rural South Africa? BMC Med. 2007 Jun 19; 5:16. PMID: 17577418.
      View in: PubMed
    50. Crespi CM, Cumberland WG, Wald A, Corey L, Blower S. Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect. 2007 Aug; 83(5):359-64. PMID: 17475687.
      View in: PubMed
    51. Vardavas R, Breban R, Blower S. Can influenza epidemics be prevented by voluntary vaccination? PLoS Comput Biol. 2007 May; 3(5):e85. PMID: 17480117.
      View in: PubMed
    52. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007 Apr 17; 146(8):591-601. PMID: 17438318.
      View in: PubMed
    53. Breban R, Vardavas R, Blower S. Theory versus data: how to calculate R0? PLoS One. 2007 Mar 14; 2(3):e282. PMID: 17356693.
      View in: PubMed
    54. Vardavas R, Blower S. The emergence of HIV transmitted resistance in Botswana: "when will the WHO detection threshold be exceeded?". PLoS One. 2007 Jan 17; 2(1):e152. PMID: 17225857.
      View in: PubMed
    55. Wilson DP, Kahn J, Blower SM. Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divide. Proc Natl Acad Sci U S A. 2006 Sep 19; 103(38):14228-33. PMID: 16968786.
      View in: PubMed
    56. Breban R, McGowan I, Topaz C, Schwartz EJ, Anton P, Blower S. Modeling the potential impact of rectal microbicides to reduce hiv transmission in bathhouses. Math Biosci Eng. 2006 Jul; 3(3):459-66. PMID: 20210374.
      View in: PubMed
    57. Breban R, Blower S. Role of parametric resonance in virological failure during HIV treatment interruption therapy. Lancet. 2006 Apr 15; 367(9518):1285-9. PMID: 16631884.
      View in: PubMed
    58. Wilson DP, Bodine EN, Smith RJ, Blower SM. Response to Foss et al., 'Care should be taken when promoting microbicide use among sex workers who are able to use condoms consistently'. AIDS. 2005 Nov 18; 19(17):2044-6. PMID: 16260916.
      View in: PubMed
    59. Blower S. Modeling the potential public health impact of imperfect HIV vaccines. J Infect Dis. 2005 Oct 15; 192(8):1494-5; author reply 1495-6. PMID: 16170769.
      View in: PubMed
    60. Breban R, Vardavas R, Blower S. Linking population-level models with growing networks: a class of epidemic models. Phys Rev E Stat Nonlin Soft Matter Phys. 2005 Oct; 72(4 Pt 2):046110. PMID: 16383471.
      View in: PubMed
    61. Wilson DP, Blower SM. Allocating antiretrovirals in South Africa: using modeling to determine treatment equity. PLoS Med. 2005 Jun; 2(6):e155; author reply e186. PMID: 15971938.
      View in: PubMed
    62. Blower SM, Bodine EN, Grovit-Ferbas K. Predicting the potential public health impact of disease-modifying HIV vaccines in South Africa: the problem of subtypes. Curr Drug Targets Infect Disord. 2005 Jun; 5(2):179-92. PMID: 15975023.
      View in: PubMed
    63. Schwartz EJ, Blower S. Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines. J Infect Dis. 2005 May 15; 191(10):1734-46. PMID: 15838802.
      View in: PubMed
    64. Smith RJ, Bodine EN, Wilson DP, Blower SM. Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. AIDS. 2005 Mar 04; 19(4):413-21. PMID: 15750395.
      View in: PubMed
    65. Crespi CM, Cumberland WG, Blower S. A queueing model for chronic recurrent conditions under panel observation. Biometrics. 2005 Mar; 61(1):193-8. PMID: 15737093.
      View in: PubMed
    66. Wilson DP, Blower SM. Designing equitable antiretroviral allocation strategies in resource-constrained countries. PLoS Med. 2005 Feb; 2(2):e50. PMID: 15737005.
      View in: PubMed
    67. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS. 2005 Jan 03; 19(1):1-14. PMID: 15627028.
      View in: PubMed
    68. Blower S, Ma L. Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. Clin Infect Dis. 2004 Nov 01; 39 Suppl 5:S240-7. PMID: 15494895.
      View in: PubMed
    69. Smith RJ, Blower SM. Could disease-modifying HIV vaccines cause population-level perversity? Lancet Infect Dis. 2004 Oct; 4(10):636-9. PMID: 15451492.
      View in: PubMed
    70. Blower S, Wald A, Gershengorn H, Wang F, Corey L. Targeting virological core groups: a new paradigm for controlling herpes simplex virus type 2 epidemics. J Infect Dis. 2004 Nov 01; 190(9):1610-7. PMID: 15478066.
      View in: PubMed
    71. Blower SM, Chou T. Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance. Nat Med. 2004 Oct; 10(10):1111-6. PMID: 15378053.
      View in: PubMed
    72. Ziv E, Daley CL, Blower S. Potential public health impact of new tuberculosis vaccines. Emerg Infect Dis. 2004 Sep; 10(9):1529-35. PMID: 15498152.
      View in: PubMed
    73. Blower S. Modelling the genital herpes epidemic. Herpes. 2004 Aug; 11 Suppl 3:138A-146A. PMID: 15319083.
      View in: PubMed
    74. Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets Infect Disord. 2003 Dec; 3(4):345-53. PMID: 14754434.
      View in: PubMed
    75. Blower S, Schwartz EJ, Mills J. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines. AIDS Rev. 2003 Apr-Jun; 5(2):113-25. PMID: 12876900.
      View in: PubMed
    76. Gershengorn HB, Darby G, Blower SM. Predicting the emergence of drug-resistant HSV-2: new predictions. BMC Infect Dis. 2003 Mar 24; 3:1. PMID: 12659657.
      View in: PubMed
    77. Blower SM, Aschenbach AN, Kahn JO. Predicting the transmission of drug-resistant HIV: comparing theory with data. Lancet Infect Dis. 2003 Jan; 3(1):10-1. PMID: 12505024.
      View in: PubMed
    78. Blower S, Volberding P. What can modeling tell us about the threat of antiviral drug resistance? Curr Opin Infect Dis. 2002 Dec; 15(6):609-14. PMID: 12821838.
      View in: PubMed